The clinical-stage biotech that decided not to block disease proteins - but to delete them.
Inside a building in San Francisco, a chemist is doing something most of pharmacology spent a century telling her was beside the point. She isn't trying to plug a protein, jam its active site, or keep it politely occupied. She is trying to get rid of it - permanently - by handing it to the cell's own recycling crew with a note that says "shred this." That note is a molecule. The crew is the ubiquitin-proteasome system. And the company built around the idea is Nurix Therapeutics.
For most of modern medicine, the dominant verb was inhibit. Find the bad protein, design a key that jams its lock, dose it forever, and hope the protein doesn't learn a workaround. It is a reasonable strategy. It is also a babysitting job that never ends. Nurix's founders - professors Michael Rape and John Kuriyan at UC Berkeley and Arthur Weiss at UCSF, scientists who helped decode how cells label proteins for disposal - asked a sharper question: why babysit a problem you could simply remove?
That is the entire thesis, and it is deceptively tidy. The field is called targeted protein degradation, and Nurix was the first company founded specifically to chase it. Where an inhibitor is a doorstop, a degrader is a demolition order. One occupies. The other erases.
Finding a molecule that can drag a specific protein to the shredder is not luck - it is search, at scale. Nurix runs a discovery platform called DELigase that fuses three things: DNA-encoded libraries (millions of candidate molecules, each barcoded with its own strand of DNA), deep biochemistry of the E3 ligases and E2 enzymes that decide what gets degraded, and machine learning. The company nicknames the AI layer DEL-AI. The output is a pipeline of degraders, modulators and degrader antibody conjugates.
NX-5948. A brain-penetrant, once-daily small molecule degrader of BTK. In a pivotal Phase 2 for relapsed/refractory CLL, with a Phase 3 planned for mid-2026 - and now globally partnered with Roche.
An oral inhibitor of the E3 ligase CBL-B - effectively a brake pedal on the immune system - in a Phase 1 across a range of oncology indications.
DNA-encoded libraries, ubiquitin biology and machine learning, working together to design molecules that recruit a target protein to its destruction.
DACs strap a protein degrader to an antibody so it can be delivered straight to a tumor cell - co-developed with Seagen, now part of Pfizer.
Medicines to outmatch disease.- Nurix Therapeutics
A platform is only as credible as the people willing to pay for it. Nurix's answer is a guest list: four of the industry's heavyweights have licensed its programs or its engine. The most recent - and largest - landed in June 2026.
June 2026: co-develop and co-commercialize bexobrutideg across hematology, immunology and neurology. $700M upfront, up to $2.3B total; costs split 40/60.
Strategic collaboration since 2019 on protein degradation therapies - $45M upfront, later extended.
Partnered since December 2019 ($55M upfront, +$22M expansion); later licensed a STAT6 autoimmune program.
2023 deal to advance degrader antibody conjugates as a new class of cancer therapeutics.
Bars are scaled to total deal value for illustration. Figures from company and partner announcements; milestone-based totals are potential, not guaranteed.
Spun out of UC Berkeley and UCSF science as the first company built for targeted protein degradation, backed by Third Rock Ventures and The Column Group.
Two strategic collaborations validate the DELigase platform before the company ever goes public.
Shares begin trading under NRIX at $19.00.
A collaboration to build degrader antibody conjugates - a new modality.
Up to $2.3B to co-develop and co-commercialize bexobrutideg, with $700M cash up front.
For a patient, the appeal is concrete. Cancers that learned to dodge BTK inhibitors are exactly the kind of "smart" disease a degrader is built to outflank - because you cannot route around a protein that no longer exists. Bexobrutideg is also brain-penetrant, which means it can chase malignant cells across the blood-brain barrier where many drugs simply stop at the door. Beyond oncology, the same logic points at autoimmune and inflammatory disease, where quieting an overactive protein could mean fewer symptoms and longer relief.
For a drug developer, Nurix is two businesses wearing one lab coat. There is the wholly-owned pipeline it intends to commercialize, led by bexobrutideg. And there is the platform itself, rented out to Roche, Sanofi, Gilead and Pfizer in exchange for upfront cash, research funding, milestones and royalties. One bet pays off slowly and enormously; the other pays the bills along the way.
Sources include Nurix Therapeutics, Roche, Gilead, Sanofi press releases, BioPharma Dive, FierceBiotech, PharmExec and Nasdaq filings. Figures involving milestones are potential totals, not guaranteed payments. Compiled June 2026.